• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Can Patent Foramen Ovales Cause Problems?
Discussion During fetal development, the heart primum and secundum septa grow and overlap leaving a small but important channel between the two atria. The foramen ovale is a flap valve moving blood from the right atrium into the left atrium directly and bypassing the high pressure pulmonary system. After birth and breathing air, the neonate’s lungs open up and the pulmonary vascular resistance decreases. The left atrium now has a relatively higher pressure than the right atria, and therefore pressure on the flap valve closes the foramen ovale. Usually within 6-12 months, the fusion of the primum and secundum of the f...
Source: PediatricEducation.org - July 24, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

EE99 Cost-Effectiveness of Percutaneous Closure of a Patent Foramen Ovale (PFO) Versus Antiplatelet Therapy After Stroke: A Trial and Model Based Economic Evaluation of the French Close Randomised Controlled Trial
The French RCT CLOSE demonstrated that patients having experienced cryptogenic stroke and having a patent foramen ovale (PFO) with echocardiographic features representing risk of stroke benefited from PFO closure compared to antiplatelet therapy. This analysis determines the cost-effectiveness from the perspective of the French healthcare system of percutaneous PFO closure in combination with antiplatelet therapy versus antiplatelet therapy alone using economic data collected during the CLOSE trial.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: M Darlington, Y Gaston, A Charles-Nelson, G Chatellier, JL Mas, I Durand-Zaleski Source Type: research

Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France
CONCLUSION: Amplatzer plus MT represents a cost-effective treatment option and is associated with lower stroke recurrence compared to MT alone for PFO patients with a prior history of stroke.PMID:34772575 | DOI:10.1016/j.jjcc.2021.10.009
Source: Journal of Cardiology - November 13, 2021 Category: Cardiology Authors: Amel Allou Louise Baschet Charles Sabourin Gilles Montalscot Luc Lorgis Xavier Iriart Source Type: research

Patent foramen ovale closure in children without cardiopathy: Child-PFO study.
CONCLUSION: Closure of patent foramen ovale in children appears to be safe and effective, as we noted a low rate of immediate complications, no delayed complications and no stroke recurrence in this indication. PMID: 32680737 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - July 13, 2020 Category: Cardiology Authors: Miton N, Godart F, Milani G, Jalal Z, Karsenty C, Baruteau AE, Gronier C, Aldebert P, Douchin S, Lucron H, Chalard A, Houeijeh A, Petit J, Hascoet S, Thambo JB, Dauphin C Tags: Arch Cardiovasc Dis Source Type: research

Reprint of : Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
CONCLUSIONS: Although a big step forward that will benefit many patients has been taken with recent trials, many questions remain unanswered. Pending results from further studies, decision-making regarding management of patients with PFO-associated ischaemic stroke should be based on a close coordination between neurologists/stroke specialists and cardiologists. PMID: 31787326 [PubMed - as supplied by publisher]
Source: Revue Neurologique - December 5, 2019 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research

Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
CONCLUSIONS: Although a big step forward that will benefit many patients has been taken with recent trials, many questions remain unanswered. Pending results from further studies, decision-making regarding management of patients with PFO-associated ischaemic stroke should be based on a close coordination between neurologists/stroke specialists and cardiologists. PMID: 31378692 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - July 31, 2019 Category: Cardiology Authors: Mas JL, Derex L, Guérin P, Guillon B, Habib G, Juliard JM, Marijon E, Massardier E, Meneveau N, Vuillier F Tags: Arch Cardiovasc Dis Source Type: research

Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study.
Conclusion: Frequency of recent ischemic stroke in patients with symptomatic PE was higher in patients with PFO than in those without PFO. This finding supports the hypothesis that paradoxical embolism is an important mechanism of ischemic stroke in patients with PFO. Primary Funding Source: French Ministry of Health. PMID: 31060047 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - May 6, 2019 Category: Internal Medicine Authors: Le Moigne E, Timsit S, Ben Salem D, Didier R, Jobic Y, Paleiron N, Le Mao R, Joseph T, Hoffmann C, Dion A, Rousset J, Le Gal G, Lacut K, Leroyer C, Mottier D, Couturaud F Tags: Ann Intern Med Source Type: research

Data Boosts Support for Abbott, Gore PFO Closure Tech
Devices designed to lower a patient's stroke risk by surgically closing a hole in the heart known as a patent foramen ovale, have historically had a tough time in clinical trials. Data from three separate studies published in the New England Journal of Medicine could go a long way toward boosting support two market-leading PFO closure devices, but figuring out who should have the procedure and who should not continues to be a gray area for clinicians and patients. Long-term results from the RESPECT trial, which evaluated the Amplatzer device that Abbott acquired when it bought St. Jude Medical, along with new data from G...
Source: MDDI - September 15, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: MD & M Minneapolis R Medical Device Business Source Type: news